Loading…
Loading…
OSAKA, Japan--(BUSINESS WIRE)--Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”) today announced the results of the phase 2 clinical study (ONO-4578-08 study) of the EP4 antagonist ONO-4578 in patients with previously untreated, HER2-negative unresectable advanced or recurrent gastric cancer (including gastroesophageal junction cancer).
OSAKA, Japan & MONTREAL--(BUSINESS WIRE)--Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President: Toichi Takino; “Ono”) announced that it has entered into an agreement to expand the drug discovery collaboration agreement with Congruence Therapeutics (Headquarters: Montreal, Quebec, Canada; CEO: Clarissa Desjardins; “Congruence”) for the discovery of novel small molecule modulators against multiple protein targets in the areas of neurology and immunology. In December 2024, we entere.
OSAKA, Japan & WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) under the accelerated approval pathway for tirabrutinib, a highly selective irreversible, second generation Bruton tyrosine kinase inhibitor, for the treatment of relapsed or refractory primar.
Ono Pharmaceutical Co., Ltd. (OPHLY) Presents at 44th Annual J.P.
Ono Pharmaceutical Co., Ltd. (OTCPK:OPHLF) Q1 FY2025 Earnings Conference Call August 1, 2025 1:00 AM ET Company Participants Hirokazu Kitada - Corporate Participant Sales and Marketing - Corporate Participant Hiroyuki Takahashi - Director of Oncology Business Division, Sales and Marketing Masaki Ito - Corporate Executive Officer & Div.
Ono Pharmaceutical Co., Ltd. (OTCPK:OPHLF) Q1 2024 Earnings Conference Call May 9, 2024 8:30 PM ET Company Participants Gyo Sagara - Representative, Director, Chairman of the Board and CEO Tatsuya Okamoto - Corporate Officer, Executive Director of Clinical Development Satoshi Takahaki - Corporate Executive Officer, Sales and Marketing Conference Call Participants Fumiyoshi Sakai - UBS Kazuaki Hashiguchi - Daiwa Hidemaru Yamaguchi - Citi Takashi Akahane - Tokai, Tokyo Unidentified Company Representative Thank you very much for your participating on FY 2023 Financial Results Meeting.
Japan's Ono Pharmaceutical Co said on Tuesday its $2.4 billion takeover of Deciphera Pharmaceuticals is a "first step" in expanding in U.S. and European markets.
Deciphera Pharmaceuticals Inc (NASDAQ: DCPH) is up a whopping 75% today after ONO Pharmaceutical (TYO: 4528) announced plans of buying it for $2.4 billion. Deciphera Pharmaceuticals stock valued at $25.60 The cash offer values each share of Deciphera Pharmaceuticals at $25.60.
No recent filings indexed.